Several groups have observed that prolonged treatment with PPARγ agonists can reduce Alzheimer’s disease pathology, demonstrating its potential therapeutic efficacy [102,136,137]. This evidence concerns the gene PPARG and early-onset autosomal dominant Alzheimer disease.